Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
25 slides from Edwards Lifesciences's conference presentation, Jan 10, 2022
Slide 1: Edwards Lifesciences at the 40th Annual J.P. Morgan Healthcare Conference
Edwards Lifesciences 40th Annual J.P. Morgan Healthcare Conference January 10, 2022 Mike Mussallem Chairman and Chief Executive Officer
Slide 2: Cautionary Statement
Cautionary Statement Presentations and comments made today by management of Edwards Lifesciences Corporation (the “Company”) will include forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, a
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Unless otherwise indicated, all figures are GAAP financial measures. The Company uses the term "adjusted sales" or “underlying growth rate” when referring to non-GAAP sales information, which excludes foreign exchange rate fluctuations, the conversion to a consignm
Slide 4: Our Credo
Our Credo Through our actions, we will become trusted partners with customers, colleagues, and patients– creating a community unified in its mission to improve the quality of life around the world. Our results will benefit customers, patients, employees and shareholders. We will celebrate our succes
Slide 5: Helping Patients Around the World
Helping Patients Around the World 600K+ 15,000+ Global Employees Patients Treated with Transcatheter Therapies ~2,000 80%+ 7 Engineers Charitable employee 50%+ Manufacturing Facilities Around the World engagement Millennials and Generation Z Investment in R&D 95%+ 17-18% Sales from Products with #1
Slide 6: Patient-Focused Innovation Strategy
Patient-Focused Innovation Strategy Innovation Leadership Focus Pioneer breakthrough Lead groundbreaking Singular focus on the large technologies with standards of care through unmet needs of structural compelling evidence trusted relationships heart and critically ill patients Create Meaningful Val
Slide 7: Edwards' patient-focused innovation strategy has produced sustained underlying sales growth
Edwards’ patient-focused innovation strategy has produced sustained underlying sales growth Focused on Track record of Long-term opportunities where triple wins: investments have patient demand is Improved outcomes yielded high-value, very large Enhanced quality of life organic growth Cost eff
Slide 8: Business Overview
Business Overview Strong Leadership Positions and Significant Growth Opportunities
Slide 9: Leader in $5B Global Transcatheter Aortic Valve Replacement Market
Leader in $5B Global Transcatheter Aortic Valve Replacement Market Estimated global Primary global growth drivers: greater awareness, advances in new technologies, as well as indication and geographic TAVR opportunity expansion $10B by 2028 Globally, diagnosis and treatment rates of AS remain low pr
Slide 10: Asymptomatic and Moderate Risk Clinical Trials
Asymptomatic and Moderate Risk Clinical Trials Expected to add significant growth beyond 2028 • Treating severe AS before symptoms may:1 • Beyond Severe Aortic stenosis, we believe our TAVR therapy may benefit patients with o Prevent irreversible myocardial damage Moderate Aortic Stenosis o Reduce r
Slide 11: Our portfolio is innovative and durable
Our portfolio is innovative and durable SAPIEN 3 Ultra System SAPIEN 3 Pulmonic + Alterra Further elevates the performance benchmark Pulmonic platform expands therapy for Next Generation TAVR of SAPIEN 3 Congenital Heart Disease patients SAPIEN X4 ALLIANCE U.S. IDE Approved in Q4 2021 + • Enhanced c
Slide 12: TMTT focused on leading and transforming treatment for mitral and tricuspid valve disease
TMTT focused on leading and transforming treatment for patients with mitral and tricuspid valve disease Three key value drivers: a portfolio of differentiated therapies, Estimated global positive results from pivotal clinical trials and excellent real- TMTT opportunity world clinical outcomes $5B by
Slide 13: TMTT has a bold vision to transform care for mitral and tricuspid patients
TMTT has a bold vision to transform care for the many patients with Mitral and Tricuspid valve disease… TRICUSPID MITRAL > 4M patients1 < 2% treated2 Poor High Ineffective quality of life mortality medical management …a comprehensive portfolio positions TMTT to realize this vision, and lead this rap
Slide 14: Building clinical evidence to transform standard of care
Building clinical evidence to transform standard of care 5 Pivotal Studies PASCAL PASCAL Functional MR PASCAL Tricuspid Degenerative MR SAPIEN M3 EVOQUE Mitral Tricuspid Strong evidence is central to expanding patient treatment 1/10/2022 14
Slide 15: Surgical Structural Heart is transforming patients' lives by solving critical unmet needs
Surgical Structural Heart is transforming patients’ lives by solving critical unmet needs in cardiac surgery Estimated global The surgical structural heart market will continue to grow surgical structural heart mid-single digits to $2B by 2028 market opportunity We closely partner with surgeons to u
Slide 16: Increasing global adoption of RESILIA accelerates long-term growth
Increasing global adoption of RESILIA accelerates long-term growth RESILIA Tissue Valves Aortic Mitral Bovine Tissue Valves INSPIRIS KONECT MITRIS Aortic valve Aortic valved conduit Mitral valve Porcine Our RESILIA portfolio is empowering patients to engage in Tissue Valves surgical valve choice for
Slide 17: Our surgical portfolio strategy enables sustained growth through innovation
Our surgical portfolio strategy enables sustained growth through innovation INSPIRIS RESILIA KONECT RESILIA MITRIS RESILIA Surgical Aortic Valve Aortic Valved Conduit Surgical Mitral Valve • Designed with expandable VFit • First pre-assembled, ready-to- • Differentiating RESILIA tissue, technology i
Slide 18: Critical Care improving the quality of care for patients
Critical Care improving the quality of care for patients Estimated global Continuing to shift product mix towards Smart Recovery, hemodynamic monitoring which has highest growth potential of our product groups market opportunity ~$2B by 2028 Focusing on three key building blocks to advance Smart Rec
Slide 19: Three Key Building Blocks for Smart Recovery
Three Key Building Blocks for Smart Recovery Smart Monitoring Platform Sensors Algorithms TECHNOLOGY T H G I S E R O F Hypotension Acumen Prediction 94 IQ Sensor Index (HPI) ForeSight Viewfinder Remote View HemoSphere Acumen IQ Cuff Hypotension Prediction Index (HPI) Data On Label ADOPTION EVIDENCE
Slide 20: Growth Outlook
Growth Outlook
Slide 21: 2021 Driving Value
2021 Driving Value Strengthening Positions Despite COVID Estimated 2021 Critical Care exceeding growth TAVR therapy and geographic expansion expectations Sales Growth: Surgical driving adoption of premium technologies TMTT implementing bold agenda High-Teens Achieving Clinical and R&D Milestones Gai
Slide 22: 2022 expected to be a year of significant milestone achievements
2022 expected to be a year of significant milestone achievements and investment in our future TAVR TMTT SURGICAL CRITICAL CARE Moderate AS trial enrollment PASCAL - DMR approval in the U.S. MITRIS approval in the U.S. HemoSphere with Viewfinder SAPIEN X4 trial enrollment EVOQUE TR approval in Europe
Slide 23: Global Market Opportunity by 2028
Global Market Opportunity by 2028 Currently around $10 billion TAVR $10B TMTT $5B Surgical $2B Critical Care Nearly ~$2B $20B 1/10/2022 23
Slide 24: Edwards is poised for long-term value creation
Edwards is poised for long-term value creation Large Populations Patient-Focused Culture Sustainable of patients with unmet needs motivates and guides our global team organic long-term sales growth Credibility and Trust Innovative R&D with clinicians, regulators, produces breakthrough therapies payo
Slide 25: Edwards
| Ee ee Edwards Helping Patients is Our Life’s Work, and, now fife?
Edwards Lifesciences — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix